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Background: Hydroxytyrosol is naturally found in olives, olive oil and wine, and is consumed as part of a normal
diet. The substance may have utility as a preservative in a wide variety of foods due to its antioxidant, antimicrobial
and amphipathic properties. The potential for hydroxytyrosol to cause chromosome aberrations in vitro had been
tested previously, with positive results at high concentrations. An OECD Guideline 475 study (mammalian bone
marrow chromosome aberration test) was conducted in rats with the oral limit dose of 2000 mg/kg bw to
determine whether hydroxytyrosol is a clastogen in vivo.
Results: The oral limit dose of 2000 mg/kg hydroxytyrosol was well tolerated by most rats; however, some rats
exhibited clinical signs that abated within 24 hours. Treatment with hydroxytyrosol did not significantly enhance
the number of aberrant cells or the mitotic index 24 or 48 hours post-dose. The positive control (cyclophosphamide)
induced the expected increase in chromosomal aberrations and a decrease in the mitotic index, confirming the validity
of the assay.
Conclusion: An oral limit dose of 2000 mg/kg hydroxytyrosol does not induce chromosome aberrations in bone
marrow cells of the rat. Accordingly, hydroxytyrosol is not a clastogen in vivo.
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Hydroxytyrosol (Figure 1) is a phenolic substance
present in olives, olive oil and wine in part per million
(ppm) quantities [1,2]. It greatly contributes to the shelf
life of olive oil, preventing its oxidation [3]. Several stud-
ies have shown that hydroxytyrosol exhibits both anti-
oxidant and antimicrobial properties [4-8], fueling
interest in the substance as a food ingredient. Hydroxy-
tyrosol could potentially be used as a preservative in a
wide variety of foods, as it is soluble in both lipid and
water fractions.
Genotoxicity testing is often required for new food in-
gredients. The ability of pure hydroxytyrosol to cause
clastogenicity has been tested previously in an in vitro
chromosome aberration test in human lymphocytes [9].
While there was no effect of the lowest concentration of
hydroxytyrosol on the number aberrant cells (excluding
gaps), the middle and high concentrations caused statis-
tically significant increases in the number aberrant cells* Correspondence: Nicole.Amann@wacker.com
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unless otherwise stated.(excluding gaps) in the presence and/or absence of a
metabolic activation system. The results of the study
suggest that at high concentrations, hydroxytyrosol may
cause clastogenicity. As recommended by the Organisation
for Economic Co-operation and Development (OECD) and
The European Food Safety Authority (EFSA), an in vivo
study should be performed to assess whether the genotoxic
potential observed in vitro is expressed in vivo [10,11]. The
purpose of the current study was to evaluate the clastogenic
potential of hydroxytyrosol in rats according to the OECD
475 Guideline (mammalian bone marrow chromosome
aberration test).
Research hypothesis
We hypothesized that hydroxytyrosol was not clasto-
genic in vivo and performed a study in rats with an oral
limit dose of 2000 mg/kg bw to test the hypothesis.
Methods
The study was conducted at BSL BIOSERVICE Scientific
Laboratories GmbH (BSL), Planegg/Munich, Germany.
Healthy Wistar rats (7–13 weeks old obtained fromThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chemical structure of hydroxytyrosol.
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tributed to five different treatment groups. Animals had
free access to feed (Altromin 1324 maintenance diet)
and tap water with the exception of an overnight fast
(minimum 16 hours) before treatment. The facilities and
procedures complied with the requirements of Commis-
sion Directive 2010/63/EU and the national legislation
defined in the animal protection law (in the version of
22 September 2010) concerning the protection of ani-
mals used for experimental and other scientific proce-
dures [12]. In accordance with European Animal
Welfare Regulations, the protocol for the study was
reviewed by members of the internal BSL ethics com-
mittee, submitted to local authorities and approved by
the Government of Bavaria “Regierung von Ober-
bayern, Fachgebiet Tierversuche und Tierschutz (Az.
55.2.1.54-2532.0-11-14; Anzeige nach § 8a Abs. 1
TierSchG; Toxizität und Genotoxizität. Based on the lit-
erature data and animal welfare, a pre-experiment was
regarded as not necessary and the study was performed as
a limit dose study. The limit dose is utilized in situations
when the test material is likely to be nontoxic, or having
toxicity at levels above regulatory limit doses, suggested by
the OECD for this study at 2000 mg/kg bw [10].
The test material was dissolved in distilled water one
hour before treatment, and administered via gavage
(10 ml/kg body weight (bw)) to two groups of five males
and five females. The oral limit dose of 2000 mg/kg (bw)
was evaluated. Two groups of five animals per sex (nega-
tive controls) were dosed with vehicle (distilled water)
only. Five male and five female rats served as positive
controls and received 40 mg/kg bw cyclophosphamide
(CPA) in physiological saline by intraperitoneal injection.
Body weights were measured prior to treatment to en-
sure that the weight of each animal was within 20% of
the mean weight of each sex, as recommended by the
guideline. All animals were examined for clinical signs of
toxicity at various time points after treatment.
Four hours before scheduled euthanization (24 and
48 hour time points for both treated and negativecontrol animals (5/sex/time-group) and 24 hours for the
positive control group), the rats received 2 mg/kg colchi-
cine (a metaphase arresting agent) by intraperitoneal
injection. At termination, femurs were removed and
bone marrow was harvested by cutting off the epiphyses
and flushing the marrow out with a potassium chloride
solution (0.4%). Collected cells were incubated (37°C for
25 min) and fixed with ten drops of ice-cold fixing solu-
tion (3:1 methanol: glacial acetic acid) under vigorous
mixing. Cell suspensions were then spun in a centrifuge
(200 x g for 10 min). The supernatant was discarded and
the sediment containing the cells was resuspended in
4 ml of ice-cold fixing solution. The fixing procedure
was repeated twice. Microscope slides were prepared by
dropping the cell suspension on clean slides, flame-drying,
and staining with Giemsa. All slides were independently
coded (blinded) before microscopic examination using
100X oil immersion objectives.
At least 100 well-spread metaphases per animal were
scored for cytogenetic damage (chromosome breaks,
fragments, deletions, exchanges and disintegrations) un-
less a distinct positive result was observed in fewer than
100 metaphases [10]. Gaps and polyploidy were recorded
but were not included in the calculation of the aberra-
tion rates. A minimum of 1000 cells per animal were an-
alyzed for mitotic index (percentage of cells in mitosis),
to determine the extent of bone marrow cell cytotox-
icity. The assay was considered valid if (1) the weights of
the rats did not exceed ± 20% of the mean weight of each
sex, (2) the negative control vehicle did not result in a
biologically significant increase in the number of cells
with chromosomal aberrations compared to historical
controls and (3) the CPA positive control produced a
biologically significant increase in the number of cells
with chromosomal aberrations. As described in the
OECD 475 guideline, the test material would be consid-
ered positive for clastogenicity if there was a clear and
dose-dependent increase in the number of cells with
aberrations and a biologically relevant response (i.e.,
greater than the laboratory historical negative control
range of 0.0% - 5.0% aberrant cells for males and 0.0% -
3.0% aberrant cells for females) for at least one dose
group. A result was considered negative if there was no
biologically relevant increase in the percentages of aber-
rant cells above concurrent controls, at any dose level.
The nonparametric Mann–Whitney test was performed
to evaluate the 24 and 48 hour post-treatment aberrant
cell (excluding gaps) and mitotic index data derived from
the test. Mean values and standard deviations were calcu-
lated for the incidence of aberrant cells in each group. For
the mitotic index, a mean value was determined per group.
Differences from the corresponding negative control
were considered to be statistically significant at the
95% confidence level (p < 0.05) for each variable examined.
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relevance was the primary criterion for interpreting the
assay results, although statistical evaluation was permitted
to aid in the interpretation. For this test biological rele-
vance and statistical significance were considered together.
Results
The mean body weights (± standard deviations) of the
male and female rats were 224.9 ± 8.4 g and 155.1 ±
7.1 g, respectively. The body weight ranges for males
(208–236 g) and females (139–165 g) were within ±6.2%
of the mean for males and ±8.4% of the mean for fe-
males, well within the ±20% recommended by the
guideline.
As shown in Table 1, after the administration of the
2000 mg/kg bw dose, 6/10 male rats showed a slight re-
duction in spontaneous activity within the first half
hour. From the 1 hour time period onward, males did
not exhibit this sign. The females did not show any signs
of toxicity during the period of treatment, with the ex-
ception of one female rat that exhibited reduced spon-
taneous activity, ataxia, wasp waist, piloerection, and
moving the bedding after 30 minutes. Some of these
findings were still present in the female after 4 hours,
but not after 24 hours. The results suggest that the oral
limit dose of 2000 mg/kg caused some signs of acute
toxicity in some, but not all animals.
Mean values of aberrant cells in the 24 and 48 hour
negative control and test groups (Table 2) were not dif-
ferent from the concurrent negative control and were
within the historical range for negative control values for
the laboratory. Therefore, treatment with hydroxytyrosol
did not significantly enhance the number of aberrant
cells at the 24 or 48 hour post-dose time points (p > 0.05
for both). Interestingly, the incidence of aberrant cells in
the male rats exposed to hydroxytyrosol for 24 hours
was lower than the negative control value (p < 0.05). The
mitotic index values for the 24 hour and 48 hour testTable 1 Clinical signs of toxicity at the oral limit dose (2000 m
Observation Tim
30 min 1 hour 2 ho
Number of animals 10/sex 10/sex 10/s
Reduced spontaneous activity 6 M, 1 F 0 M, 1 F 0 M,
Ataxia 0 M, 1 F 0 M, 1 F 0 M,
Wasp waist 0 M, 1 F 0 M, 1 F 0 M,
Piloerection 0 M, 1 F 0 M, 1 F 0 M,
Moving the bedding 0 M, 1 F 0 M, 1 F 0 M,
Salivation 0 M, 1 F 0 M, 0 F 0 M,
Prone position 0 M, 1 F 0 M, 0 F 0 M,
F = females; M =males.groups were not different from the values for the corre-
sponding negative controls, indicating that hydroxytyro-
sol was not toxic to the cells at the administered dose.
The positive control induced the expected increase in
chromosomal aberrations and a decrease in the mitotic
index (p < 0.05). The validity of the assay was verified by
(1) the weight variation of the rats not exceeding ± 20%
of the mean weight of each sex, (2) the lack of biologic-
ally significant increases in aberrant cell values in the
negative control group, and (3) the significant induction
of aberrant cells in the CPA positive control group.Discussion
The results of the current study indicate that at an
oral limit dose of 2000 mg/kg bw, hydroxytyrosol does
not cause a statistically significant increase in the
number aberrant cells (excluding gaps) in the bone
marrow of rats. These results contradict results of a
previous in vitro chromosome aberration test in hu-
man lymphocytes [9]. The latter study showed a statis-
tically significant increase in the number of human
lymphocytes with chromosomal aberrations (excluding
gaps) when treated with 287.7 μg/mL hydroxytyrosol
(1.9 mM) in the presence of S9 (3.5% in treated vs.
0.5% in control), or 503.5 μg/mL (3.3 mM) hydroxy-
tyrosol in the absence (9.0% in treated versus 0.5% in
control) or presence of S9 (4.5% in treated vs. 0.5% in
control). There was no effect of 164.4 μg/mL
(1.1 mM) hydroxytyrosol (the lowest dose tested) on
the incidence of human lymphocytes with chromo-
somal aberrations in the absence or presence of S9.
The test was considered valid, as the positive controls
showed distinct increases in cells with chromosomal
aberrations including or excluding gaps. The reason
for the positive response in vitro is unknown, but may
be related to the anti-oxidative nature of hydroxytyro-
sol. A number of antioxidants have been shown tog/kg bw)
e (post application)
urs 3 hours 4 hours 24 hours 48 hours
ex 10/sex 10/sex 10/sex 10/sex
1 F 0 M, 1 F 0 M, 1 F 0 M, 0 F 0 M, 0 F
1 F 0 M, 1 F 0 M, 0 F 0 M, 0 F 0 M, 0 F
0 F 0 M, 0 F 0 M, 0 F 0 M, 0 F 0 M, 0 F
1 F 0 M, 1 F 0 M, 1 F 0 M, 0 F 0 M, 0 F
1 F 0 M, 0 F 0 M, 0 F 0 M, 0 F 0 M, 0 F
0 F 0 M, 0 F 0 M, 0 F 0 M, 0 F 0 M, 0 F
0 F 0 M, 0 F 0 M, 0 F 0 M, 0 F 0 M, 0 F
Table 2 Summary of chromosome aberration assay results
Study groups (n = 5/sex) Metaphases Aberrant cells excluding gaps Gaps Polyploid cells Mitotic index (% ± SD)
Number (% ± SD)
Negative Control, 24 h
Male 500 6 1.2 ± 1.1 5 0 11.3
Female 500 5 1.3 ± 1.4 8 0 8.4
Treatment Group, 24 h
Male 500 0 0.0 ± 0.0* 4 0 11.0
Female 500 2 0.4 ± 0.9 7 0 10.1
Negative Control, 48 h
Male 500 3 0.6 ± 1.6 4 4 10.7
Female 500 0 0.0 ± 0.0 3 0 11.4
Treatment Group, 48 h
Male 500 1 0.2 ± 0.4 5 0 14.3
Female 500 1 0.2 ± 0.4 3 1 13.4
Positive Control, 24 h
Male 250 100 40.0 ± 12.3* 6 1 3.1*
Female 250 108 43.2 ± 4.9* 11 0 2.5*
*Significantly different from negative control (distilled water) (p < 0.05).
n = number of animals; SD = standard deviation.
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at high concentrations [13].
A possible reason for the negative result in vivo and
the positive result in vitro is that the concentrations
used in the in vitro study were higher than the con-
centration present in the serum of rats exposed to an
oral limit dose of 2000 mg/kg bw. In rats provided 55 mg/
kg bw hydroxytyrosol by the oral route, the maximal
plasma concentration of hydroxytyrosol is 0.89-3.26 μg/ml
(5.7 – 21 μM) [14]. Assuming absorption of hydroxytyrosol
increases linearly with concentration, the maximal plasma
concentration of hydroxytyrosol in rats exposed to the
2000 mg/kg limit dose in the current study may have
reached 0.21 – 0.76 mM (32 – 115 μg/mL), which is
lower, but not much different, than the lowest concen-
tration of hydroxytyrosol used in the in vitro study
(1.1 mM, also expressed as 164.4 μg/mL). Therefore,
the lack of clastogenic effect at the lowest dose in the
recent in vitro study [9] is in agreement with the re-
sults in the current in vivo study. There is also a low
potential for cytotoxic actions in this or the in vitro
study, as hydroxytyrosol has been found to inhibit
hydrogen peroxide-induced cytotoxicity at 0.25 mM
[15], a concentration similar to the calculated maximal
plasma concentration in the current study. In vitro,
hydroxytyrosol decreases cytotoxic actions in rat liver
slices at a concentration of 50 μg/mL [16], within the
range of the calculated rat plasma hydroxytyrosol
levels determined in the current study. In healthy
humans ingesting 25 ml virgin olive oil, the maximumplasma concentration of hydroxytyrosol is 26 μg/L
(0.17 μM) [17], more than 6470 times lower than the
lowest concentration of hydroxytyrosol used in the
in vitro study. Because the positive results in the
in vitro study were obtained with high concentrations
of hydroxytyrosol that are not physiologically feasible
(even in rats dosed with 2000 mg/kg bw hydroxytyro-
sol or a heavy consumer of olive oil), they are irrele-
vant for assessing risk of genotoxicity from
consumption of hydroxytyrosol. The oral bioavailability of
hydroxytyrosol when administered in olive oil or in an
aqueous solution was found to be 99% and 75%, respect-
ively, but is also rapidly eliminated in the urine due to
preferential renal uptake of hydroxytyrosol [18]. The ma-
jority of hydroxytyrosol and its primary metabolites (sulfo-
conjugated derivative, 3,4-dihydroxyphenylacetaldehyde
and 4-hydroxy-3-methoxyphenylacetic acid) are re-
moved from the body within the first 24 hours [18,19].Conclusion
Based on the negative findings of the OECD Guideline
475 study with the limit dose in rats, one can conclude
that there is no risk of clastogenicity of hydroxytyro-
sol, even in heavy consumers of olive oil or potential
users of foods containing hydroxytyrosol as an added
ingredient.
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